Cardiology

Research Abstract

C12 - Effects of BNP-32 in Dogs with Congestive Heart Failure Due to Myxomatous Mitral Valve Disease

Friday, June 15
1:30 PM - 1:45 PM
Location: WSCC 613/614

Synthetic brain natriuretic peptide (BNP-32) causes natriuresis, diuresis, vasodilation, and RAAS antagonism in dogs with experimentally induced congestive heart failure (CHF); however, it is unclear as to whether dogs with naturally occurring CHF would respond similarly. The purpose of this pilot study was to evaluate the efficacy of synthetic canine BNP-32 given subcutaneously in dogs with naturally occurring CHF.

Seven client-owned male dogs with compensated ACVIM Stage C CHF due to myxomatous mitral valve disease received single doses of subcutaneous BNP-32 (5 ug/kg), frusemide (2 mg/kg), and both BNP-32/frusemide (5 ug/kg and 2 mg/kg, respectively) in a cross-over study design with a two-week washout period between each treatment. Heart rate (HR), blood pressure (BP), plasma concentrations of BNP-32 and cGMP, and fractional excretion of sodium (FENa) and potassium (FEK) were measured at 0, 1, and 3 h following treatment. Urine output (UOP) and urinary cGMP production (UPcGMP) were measured at 0, 1, 2, and 3 h following treatment. Between- and within-treatment effects were evaluated using linear mixed modelling with restricted maximum likelihood estimation. Significance was taken at p < 0.05.

Frusemide and BNP-32/frusemide resulted in a significant increase in UOP, FENa, and FEK from 1 – 3 h post treatment. However, there were no differences between these two treatments, and BNP-32 alone did not affect these parameters. No changes in HR or BP were observed with any of the treatments. Plasma concentrations of BNP-32 increased significantly within 1 h of treatment for both treatments containing BNP-32, but fell to baseline by 3 h post treatment. Although no significant differences in plasma concentrations of cGMP were observed, the UPcGMP increased significantly from 1 – 2 h following treatment with BNP-32 and BNP-32/frusemide.

Subcutaneous BNP-32 resulted in an increase in plasma BNP-32 concentrations and UPcGMP. However, there were no detectable biological effects on HR, BP, UOP, FENa, and FEK. This is in contrast to data obtained from dogs with experimentally induced CHF. Though further investigations are recommended, it is possible that dogs with naturally occurring CHF may have a reduction in natriuretic peptide responsiveness. 

Mariko Yata, BVSc (hons), MANZCVS (Small Animal Medicine)

PhD Candidate
Sydney School of Veterinary Science, Faculty of Science, University of Sydney

Mariko graduated from the University of Sydney with first class honours in 2007 and began working in a small animal general practice in Canberra. Since moving back to Sydney in 2009, she has worked as an emergency and critical care veterinarian at referral clinics across Sydney. She obtained membership in small animal medicine through the Australian and New Zealand College of Veterinary Scientists in 2012. Mariko has a particular interest in the field of veterinary cardiology and, in 2013, she commenced a PhD investigating therapeutics of canine and feline congestive heart failure at the University of Sydney.

Presentation(s):

Send Email for Mariko Yata


Assets

C12 - Effects of BNP-32 in Dogs with Congestive Heart Failure Due to Myxomatous Mitral Valve Disease

Handout

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Effects of BNP-32 in Dogs with Congestive Heart Failure Due to Myxomatous Mitral Valve Disease